Download presentation
Presentation is loading. Please wait.
Published byΑμάραντος Διδασκάλου Modified over 6 years ago
1
Welcome to Graduate School of Biomedical Sciences (GSBS)
at the U T Health Science Center at Houston and M D Anderson Cancer Center August 20, 2018 Mien-Chie Hung, Ph.D. Vice President for Basic Research Professor and Chair Department of Molecular and Cellular Oncology
2
You come to the best place
Congratulations You come to the best place to do cancer research & for graduate studies
3
Cell Biology Physiology Cancer Biology NRC S ranking in 2010,
122 programs
4
Since the survey began in 1990, MD Anderson has been named one of the top two cancer hospitals, and it has ranked first 14 times in the last 17 years.
5
It has ranked first 14 times in the last 17 years.
MD Anderson remains the the leading hospital in the US. It has ranked first 14 times in the last 17 years. GSBS partners with MD Anderson in cancer research.
6
Training Opportunities
Scientific Thinking and Bench Skills Writing and Oral Presentation Training Retreats & Social Event to meet the leaders in academy (Noble Laureates, Members of National Academy of Sciences), industry, patent law and others , Learn how to be successful
7
Research Achievements & Awards
High impact publications National and State Awards, NIH F31, DOD UT system and GSBS prestigious awards and scholarship
8
PTEN loss induced by astrocyte-derived exosomal microRNA primes brain metastasis outgrowth via cross-talk between tumor cells and brain metastatic microenvironment. L. Zhang, S. Zhang, …, D. Yu, Nature, 11/2015
9
A common pathway shared between cancer and diabetes
Breast Cancer Fat cells Energy Diabetes Dung-Fang Lee 2004 Cell 2007 Cell 2009 Mol Cell UT HSC CPRIT awardee
10
The University of Texas System Regents’ Outstanding Teaching Award
Mien-Chie Hung
11
The University of Texas System Regents’ Outstanding Teaching Award
Dihua Yu Naoto Ueno Mien-Chie Hung 青出於藍而勝於藍
12
GSBS alumni in industry, a few examples
Jing Shan Jennifer Hu Vice President and Head of Innovation Center China Global Drug Discovery Bayer Health Pharmaceuticals Kerry Russell Vice President, Clinical Development at resTORbio 2004 Cell, cited: 550, 2007 Cell, cited: 297 2005 Science, cited: 231
13
Institute for Applied Cancer Science Institute for Basic Science
Research Opportunities Institute for Applied Cancer Science Institute for Basic Science Institute for Cancer Care Innovation Duncan Family Institute McCombs Institute Zayed Institute for Personalized Cancer Therapy
14
Institute for Applied Sciences (IACS)
VP, Therapeutic Discovery and Head of Drug Discovery: Phil Jones, PhD Co-leader, Moon Shot Programs and IACS & SVP, Therapeutic Discovery Giulio Draetta, MD, PhD, Mission To apply scientific knowledge of mechanisms driving tumor development and maintenance into the development of impactful small molecule cancer therapies.
15
Institute of Basic Science
Research Institute of Basic Science Director: Mien-Chie Hung, PhD. Biological Pathways Cancer Epigenetics Environmental and Molecular Carcinogenesis Genetics and Genomics Inflammation and Cancer Stem Cell and Developmental Biology
16
2018 Albany Medical Center Prize in Medicine and Biomedical Research
James P. Allison, Ph.D., The University of Texas MD Anderson Cancer Center Carl June, M.D., Perelman School of Medicine, University of Pennsylvania Steven A. Rosenberg, M.D., Ph.D., National Cancer Institute, National Institutes of Health $500,000, they are being recognized for their contributions to research that established immunotherapy as a revolutionary and effective method to treat cancer and other diseases
17
Targeting PD-L1 glycosylation enhances anti-tumor immunity
B C D d E e Li, Lim, et al, Cancer Cell, 2018, Feb StCube,Inc
18
2018 Tang Prize in Biopharmaceutical Science
Brian Druker, The Knight Cancer Institute, Oregon Health & Science University Tony Hunter, The Salk Institute John Mendelsohn, The University of Texas MD Anderson Cancer Center $1.33 mils
19
Lung cancer is the leading cause of cancer death in both man and women for more than 6 years.
20
Lee, et al, Cancer Cell 2018 Sep.
PKCδ serves as a common therapeutic target for resistance of EGFR kinase inhibitors and an option for treatment. Tumor size (mm3) H1975 tumor (T790M+) Control AZD9291 Sotra AZD+Sotra Days after treatment TM0204 PDX (T790M+) EGFR activation-mutation occurs in about 50% Asia and 15% Caucasian NSCLC cancer population. EGFR kinase inhibitors suppress tumor development and patients survive for a couple of years, but eventually tumors develop with multiple resistant mechanisms leaving no effective option for patients. Lee, et al, Cancer Cell 2018 Sep.
21
Heart
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.